19-Dec-2025
Top Cencora Executive Makes Major Move With Insider Stock Sale
TipRanks (Fri, 19-Dec 9:03 PM ET)
TipRanks (Wed, 17-Dec 7:20 AM ET)
Cencora’s Strategic Acquisition: Hold Rating Amid Limited Near-Term Financial Upside
TipRanks (Tue, 16-Dec 6:36 AM ET)
Cencora Announces Acquisition of OneOncology for $3.6 Billion
TipRanks (Mon, 15-Dec 7:30 AM ET)
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
Business Wire (Mon, 15-Dec 7:00 AM ET)
Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results
Business Wire (Wed, 5-Nov 6:30 AM ET)
Business Wire (Thu, 16-Oct 9:00 AM ET)
Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release
Business Wire (Mon, 6-Oct 4:30 PM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of December 19, 2025, COR stock price climbed to $340.93 with 2,378,249 million shares trading.
COR has a beta of 0.00, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $66.09 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $84 billion in Revenue and $3.84 earnings per share. This beat revenue expectation by $428 million and exceeded earnings estimates by $.05.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has outperformed the market in the last year with a price return of +51.7% while the SPY ETF gained +18.1%. COR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.8% and +0.4%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
COR support price is $335.77 and resistance is $345.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.